Pfizer

New York, United States Founded: 1849 • Age: 177 yrs Listed
Pharmaceutical products for treating multiple diseases are provided.
Request Access
Report Incorrect Data
Page last updated

About Pfizer

Pfizer is a publicly listed company based in New York (United States) founded in 1849. Pharmaceutical products for treating multiple diseases are provided. Pfizer has raised $8 million across 11 funding rounds from investors including Gates Foundation, European Union and Tekla Capital Management. The company has 1,770 employees. Pfizer has completed 43 acquisitions, including Alacer, Allergan and Amplyx Pharmaceuticals. Its chief executive, as recorded, is Albert Bourla. Its website pfizer.com draws about 1.9 million monthly visits. Its Indian entity Pfizer Limited reported revenue of ₹2,708 Cr. Its focus areas include Diversified Pharmaceuticals, Drugs, Pharmaceutical Distributors and Generic Drugs. Its competitors include Roivant Sciences, AbbVie and Gilead; 1 of its 3 listed competitors has raised funding.

Company details

Founded in 1849 and headquartered in New York, United States, operations in the pharmaceutical sector are conducted. A variety of products for disease treatments is developed, including a cancer medicine that inhibits tumor blood supply and disrupts cellular reproduction. Chantix is available to support smoking cessation. In 2022, annual revenues reached 92.95 billion, with net profit at 29.04 billion. Leadership is held by CEO Albert Bourla.

  • Headquarters New York, United States
  • Employees 1,770
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Phone
    •••• ••••
  • Website pfizer.com
  • Social LinkedIn X Facebook
  • Legal Name Pfizer Limited
  • Date of Incorporation 21 Nov, 1950
  • Jurisdiction Mumbai, Maharashtra, India
Operational Areas
Healthcare → Pharmaceuticals & Distribution
Healthcare → Biopharma Outsourcing & Drug Delivery
Healthcare → Pharmaceuticals & Distribution
Key Metrics
  • Market Cap
    ₹17,644 Cr

    PFIZER · NSE

  • Share Price
    ₹3,856.00

    -0.02% today

  • Revenue
    ₹2,520 Cr

    FY 2025-26 · +10.5% YoY

  • EBITDA
    ₹855 Cr

    Margin 33.9%

  • Net Profit
    ₹759 Cr

    FY 2025-26 · +37.5% YoY

  • P/E (TTM)
    21.5x

    P/B 3.7x

  • ROE
    17.2%

    ROCE 22.6%

  • Debt / Equity
    0.02

    Interest cover 1.2x

  • Total Equity Funding
    $8M (USD)

    in 11 rounds

  • Latest Funding Round
    $117.44M (USD), Grant

    Jun 2023

  • Investors
    Gates Foundation

    & 4 more

  • Employee Count
    1,770
  • Investments & Acquisitions
    Alacer

    & 42 more

Apps and channels of Pfizer

Pfizer publishes 1 mobile app with over 500 downloads.

LivingWith™ Ulcerative Colitis
Google Play Health & Fitness Everyone Free 500 downloads
Developer: Pfizer Inc.
View on Google Play

Funding Insights of Pfizer

Pfizer has successfully raised a total of $8M across 11 strategic funding rounds. The most recent funding activity was a Grant round of $117.44 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $8M
  • Total Rounds 11
  • Last Round Grant — $117.44M
  • First Round $10.74B

    (Jun 2009)

  • Investors Count 5

Latest 10 of 11 funding rounds of Pfizer with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2023$117.44MGrant––
European Union
Jan 2020Grant––
European Union
Sep 2018$5BDebt – Conventional––
–
Jul 2018$1MGrant––
Michigan Economic Development
May 2018$8MSeed––
–
May 2017Grant––
Gates Foundation
Apr 2016$200MPost-IPO––
NovaQuest Capital Management
Jan 2016$110,572Grant––
European Union
Sep 2015$30.31MPost-IPO––
Tekla Capital Management
Jan 2015$42,065Grant––
European Union
Valuation history

5 investors in total: 5 institutional.

Investors in Pfizer

Pfizer has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, European Union and Tekla Capital Management.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
NovaQuest Capital Management
PE firm focused on life science and healthcare companies
novaquest.comRaleigh, United States
European Union
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
1958europa.euBrussels, Belgium
Michigan Economic Development
Economic development in Michigan is advanced by the foundation.
1997michiganadvantage.orgLansing, United States
Gates Foundation
Charitable foundation investments on poverty reduction and healthcare
2000gatesfoundation.orgSeattle, United States
Tekla Capital Management
Investment advisory services are provided to financial clients.
1986teklacap.comBoston, United States
Premium access

Investor details for Pfizer

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Pfizer Limited (Pfizer)

Pfizer Limited is the primary company behind Pfizer. The boards of the 4 registered companies of Pfizer currently have 21 directors; the longest-serving is Pradip Panalal Shah, appointed in 1999. 98 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Pradip Panalal Shah
DIN 00066242
Director07 Dec 199926 yrs 10 moPfizer Limited
Andrew David Chatfield
DIN 07086776
Director20 Dec 20187 yrs 10 moPfizer Healthcare India Private Limited
Meena Ganesh
DIN 00528252
Director08 Mar 20197 yrs 8 moPfizer Limited
Kannan Natarajan
DIN 08389067
Director13 Mar 20197 yrs 7 moPfizer Healthcare India Private Limited
Seema Shantharam Pai
DIN 08731469
Whole-time director25 Sep 20206 yrs 1 moPfizer Products India Private Limited
Darshak Pradip Bhagat
DIN 08731421
Director31 Mar 20215 yrs 7 moPfizer Products India Private Limited
Shabbar Abid Vhora
DIN 09160521
Whole-time director29 Sep 20215 yrs 1 moPfizer Products India Private Limited
Hemant Kumar Manilal Mamania
DIN 09455299
Director03 Jan 20224 yrs 10 moWatson Pharma Private Limited
Nishank Bhargava
DIN 09472446
Director24 Feb 20224 yrs 8 moWatson Pharma Private Limited
Jayaraman Aparajith
DIN 09430513
Company Secretary28 Jul 20224 yrs 3 moPfizer Healthcare India Private Limited
Fiona Kathleen Maccarthy
DIN 10051316
Director20 Feb 20233 yrs 8 moPfizer Healthcare India Private Limited
Meenakshi Nevatia
DIN 08235844
Managing Director03 Apr 20233 yrs 7 moPfizer Limited
Pazhania Pillai Rengan
DIN 10362899
Whole-time director06 Jan 20242 yrs 10 moPfizer Limited
Andrew Gordon Mc Killop
DIN 10478137
Director25 Jan 20242 yrs 9 moPfizer Healthcare India Private Limited
Amit Agarwal
DIN 10465938
Whole-time director30 Mar 20242 yrs 7 moPfizer Limited
Agnieszka Monika Lubkowska
DIN 10611360
Director26 Jun 20242 yrs 4 moWatson Pharma Private Limited
Wriju Ghosh
DIN 10688477
Director29 Jun 20242 yrs 4 moPfizer Healthcare India Private Limited
Lakshmanan Krishna Kumar
DIN 00423616
Director29 Jul 20242 yrs 3 moPfizer Limited
Sonia Singh
DIN 07108778
Director29 Jul 20242 yrs 3 moPfizer Limited
Muralidhar B Sharma
DIN 10877658
Director19 Dec 20241 yr 10 moPfizer Healthcare India Private Limited
Chandrasekhar Bhagwan Sinha
DIN 11212924
Director08 Aug 20251 yr 2 moWatson Pharma Private Limited

People of Pfizer

1483 people are tracked at Pfizer (767 in leadership, 12 in board & advisors, 704 in team); the tracked headcount is 1,770.

NameRoleGroup
Albert Bourla
CEOLeadership
Ian C Read
CEOLeadership
James Farrelly
VP - R&d Digital Platform LeadLeadership
John Harrold
Senior Director Of PharmacometricsLeadership
Tomas Kaplan
Director - Commercial Strategy & Innovation (csi)Leadership
Sue Diviney
VP & Office of the Ombuds LeadLeadership
Roger Luebbe
Director/controller US Sterile Injectable NetworkLeadership
Andrew Muratore
VP & Assistant General Counsel, Mergers & Acquisitions, And Chief Counsel, Pfizer VenturesLeadership
Michael Comeaux
Director Product Integrity Corporate Compliance Global SecurityLeadership
Dave Boyd
Project Director Technology SupportLeadership
Sriram Krishnaswami
Head, R&d Portfolio And InnovationLeadership
Michael Hovanyetz
Senior Director, Commercial Enterprise SolutionsLeadership
Jon Ross
Director Site Supply Operations, North CreekLeadership
Torres Ernesto
Director, Physical Risk Mitigation, Global SecurityLeadership
Angela Wasunna Rwiliriza
Chief Counsel, Corporate Affairs, Policy And PrivacyLeadership
William McDaniel
Director/team Leader, External Supply - Biotech Emerging MarketsLeadership
Don Desantis
Director Salesforce EnablementLeadership
Luiz Arantes
Vice President U.s. Specialty Care Medical LeadLeadership
Veronica Garcia
Director, Business Relationship ManagerLeadership
Waqas Mahmood
Global Procurement Manager (pakistan And Japan)- Business Engagement Partner & Chief Of StaffLeadership

1463 more people are available in the full profile.

Premium access

Complete people profiles for Pfizer

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Pfizer

Pfizer is a publicly listed company on the NSE with ticker symbol PFIZER in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date24 Nov 2023
  • Listed onEuronext: 1PFE
  • Listed entityPFIZER LIMITED
  • Exchange sectorHealth technology

Financials of Pfizer

Exchange-reported figures of Pfizer Limited, the listed company behind Pfizer (NSE: PFIZER).

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹2,520 Cr
+10.4% YoY
EBITDA
₹855 Cr
+15.5% YoY
Profit After Tax
₹759 Cr
+37.5% YoY
Net Worth
₹4,203 Cr
-0.3% YoY
Total Assets
₹4,329 Cr
-1.2% YoY
Total Debt
₹70.23 Cr
-35.2% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,5202,2812,1932,4252,6112,2392,152
Revenue growth+10.5%+4.0%-9.6%-7.1%+16.6%+4.0%-
EBITDA855740635809836712573
EBITDA margin+33.9%+32.5%+29.0%+33.4%+32.0%+31.8%+26.6%
Profit before tax9761,016746824773669642
Net profit759552548601611498510
Net profit margin+30.1%+24.2%+25.0%+24.8%+23.4%+22.2%+23.7%
EPS (₹)157.91167.78120.51136.38133.89108.77111.29
Balance sheet
Total assets4,3294,3823,7223,3853,0872,5553,535
Net worth4,2034,2173,5963,2072,8642,3933,395
Total debt70.2310840.1941.1539.2563.232.50
Cash & bank3,1112,8012,0471,8601,6431,1152,220
Net working capital3,2102,9842,2311,9091,5831,1972,177
Cash flow
Cash from operations968660257356667427323
Cash from investing(562)(71.34)53.70(36.05)(575)(469)1,530
Cash from financing(798)(205)(235)(346)(181)(1,571)(164)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue727653629645642603592538
Revenue growth (YoY)+13.2%+8.3%+6.3%+19.9%+9.1%+7.1%--
Other income17944.8449.7638.2141.8567.1721742.76
Total expenses466406393475412393364392
EBITDA261248236170230210228146
EBITDA margin+35.9%+37.9%+37.5%+26.4%+35.8%+34.8%+38.4%+27.1%
Depreciation14.4114.2614.7814.2614.2814.4116.4014.80
Interest3.351.462.111.992.133.252.691.51
Profit before tax423277269192255260426172
Tax11072.2169.0050.1166.3567.7894.8644.84

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 06 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue727653629645642603592538
Revenue growth (YoY)+13.2%+8.3%+6.3%+19.9%+9.1%+7.1%--
Other income17944.8449.7638.2141.8567.1721742.76
Total expenses466406393475412393364392
EBITDA261248236170230210228146
EBITDA margin+35.9%+37.9%+37.5%+26.4%+35.8%+34.8%+38.4%+27.1%
Depreciation14.4114.2614.7814.2614.2814.4116.4014.80
Interest3.351.462.111.992.133.252.691.51
Profit before tax423277269192255260426172
Tax11072.2169.0050.1166.3567.7894.8644.84
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,5202,2812,1932,4252,6112,2392,152
Revenue growth+10.5%+4.0%-9.6%-7.1%+16.6%+4.0%-
Other income18834518813462.6581.12184
Total expenses1,6651,5411,5581,6161,7751,5261,579
Employee cost368371348332404361365
EBITDA855740635809836712573
EBITDA margin+33.9%+32.5%+29.0%+33.4%+32.0%+31.8%+26.6%
Depreciation57.7360.7962.28106115109103
Interest9.578.5015.4313.4810.7015.3911.01
Profit before tax9761,016746824773669642
Tax253248195200160171133
Net profit759552548601611498510
Net profit margin+30.1%+24.2%+25.0%+24.8%+23.4%+22.2%+23.7%
EPS (₹)157.91167.78120.51136.38133.89108.77111.29
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital45.7545.7545.7545.7545.7545.7545.75
Reserves & surplus4,1574,1723,5503,1622,8192,3473,350
Shareholders' funds (net worth)4,2034,2173,5963,2072,8642,3933,395
Secured loans0.000.000.000.000.000.000.00
Unsecured loans70.2310840.1941.1539.2563.232.50
Total debt70.2310840.1941.1539.2563.232.50
Total liabilities4,3294,3823,7223,3853,0872,5553,535
Assets
Gross block1,4181,4181,3561,3521,3831,3161,315
Net block678724713749869894973
Capital work in progress20.007.640.407.931.152.760.76
Investments0.000.000.000.000.000.000.00
Inventories473476434418449435431
Sundry debtors182193188152143109172
Cash & bank balances3,1112,8012,0471,8601,6431,1152,220
Loans & advances38.0042.8669.8096.14162250226
Total current assets3,8033,5132,7382,5252,3961,9083,048
Total current liabilities593529506616814711871
Net working capital3,2102,9842,2311,9091,5831,1972,177
Total assets4,3294,3823,7223,3853,0872,5553,535
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash49511236.6062.761511,76473.81
Net cash from operating activities968660257356667427323
Net cash from investing activities(562)(71.34)53.70(36.05)(575)(469)1,530
Net cash from financing activities(798)(205)(235)(346)(181)(1,571)(164)
Net change in cash(392)38375.40(26.16)(88.45)(1,613)1,690
Closing cash3,1112,8012,0471,8601,6431,1152,220
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+10.5%+4.0%-9.6%-7.1%+16.6%+4.0%-
EBITDA growth+15.5%+16.5%-21.5%-3.2%+17.3%+24.4%-
PBT growth-4.0%+36.2%-9.5%+6.6%+15.6%+4.1%-2.6%
Net income growth+37.5%+0.8%-8.9%-1.7%+22.9%-2.4%-
Revenue CAGR (3Y)+1.3%-4.4%-0.7%+4.1%+7.9%+4.4%+3.1%
EBITDA CAGR (3Y)+1.9%-4.0%-3.8%+12.2%+13.9%+12.5%+17.8%
Profitability & leverage
Net income margin+28.7%+33.7%+25.1%+25.7%+23.5%+22.2%+23.7%
Return on capital employed+22.6%+21.1%+21.4%+25.9%+27.8%+22.5%+19.9%
Return on net worth+17.2%+16.4%+16.2%+20.6%+23.3%+17.2%+15.9%
Debt / equity0.020.020.010.010.020.010.00
Long-term debt / equity0.010.010.000.000.000.000.00
Interest cover1.201.252.691.921.482.552.35
Efficiency & per share
Fixed asset turnover1.781.641.621.771.931.701.75
Inventory turnover5.315.025.155.605.915.175.27
Debtors turnover13.4411.9912.9316.4820.7815.9412.52
EPS (₹)157.91167.78120.51136.38133.89108.77111.29
Dividend per share (₹)75.00165.0035.0040.0035.0035.00330.00
Book value per share (₹)918.67921.84785.91701.05626.10523.07742.18

Investments & Acquisitions by Pfizer

Pfizer has strategically engaged in corporate development activities, having acquired 43 companies. Notable acquisitions include Alacer, Allergan and Amplyx Pharmaceuticals.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Metsera
Biopharmaceuticals for obesity and metabolic diseases are developed.
metsera.comNew York, United States2022Sep 2025$4.9B
Seegene Technologies
Developer of molecular diagnostic kits to detect infectious and genetic diseases
seegene.comSeoul, South Korea2000Mar 2023$43B
Pfizer
Antibody-drug conjugates for cancer treatment are developed.
seagen.comBothell, United States1998Mar 2023$43B
Biohaven
Therapeutics for neurological and neuropsychiatric diseases are developed.
biohaven.comNew Haven, United States2022Oct 2022••••
GBT
Small molecules are developed for sickle cell disease treatment.
gbt.comSan Francisco, United States2011Aug 2022$5.4B
Biohaven Pharmaceutical
Therapies for neurological and neuropsychiatric diseases are developed.
biohavenpharma.comNew Haven, United States2014May 2022$11.6B
ReViral
Antiviral compounds for Respiratory Syncytial Virus infections are developed.
reviral.co.ukLondon, United Kingdom2011Apr 2022••••
Arena Pharmaceuticals
Clinical-stage biotech focused on cardiovascular, autoimmune, inflammatory and metabolic diseases.
arenapharm.comSan Diego, United States1997Dec 2021$6.7B
Trillium Therapeutics
Cancer therapeutics targeting immune evasion pathways are developed.
trilliumtherapeutics.comToronto, Canada1996Aug 2021$2.2B
Amplyx Pharmaceuticals
Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma.
amplyx.comSan Diego, United States2006Apr 2021••••
Premium access

Complete acquisition details for Pfizer

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Pfizer

14 dated milestones of Pfizer across 176 years, from founding to its latest funding, stage changes and deals.

  1. Founded Pfizer is founded.
  2. Funding First funding round of $10.7B.
  3. Acquisition Acquires Amplyx Pharmaceuticals.
  4. Acquisition Acquires Trillium Therapeutics.
  5. Acquisition Acquires Arena Pharmaceuticals.
  6. Acquisition Acquires ReViral.
  7. Acquisition Acquires Biohaven Pharmaceutical.
  8. Acquisition Acquires GBT.
  9. Acquisition Acquires Biohaven.
  10. Acquisition Acquires Seegene Technologies.
  11. Acquisition Acquires Pfizer.
  12. Funding Latest funding round, Grant, of $117.4M.
  13. IPO Lists on the stock exchange (IPO).
  14. Acquisition Acquires Metsera.

Competitors of Pfizer

Pfizer has 3 listed competitors in our database, 1 of them funded. They include Roivant Sciences, AbbVie and Gilead.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Roivant Sciences
roivant.com2014New York, United States$1.3B662
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
AbbVie
abbvie.com2012Chicago, United States8,667
Biopharmaceutical research and drug development are conducted globally by AbbVie.
Gilead
gilead.com1987Foster, United States4,267
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
Premium access

Detailed competitors of Pfizer

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Pfizer

The website of Pfizer (pfizer.com) receives about 1.9M visits a month and ranks #24,984 among all websites worldwide, #570 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    1.9M

    ▼ 27.1% vs previous month

  • Unique visitors
    1.5M

    per month

  • Global rank
    #24,984

    among all websites

  • Category rank
    #570

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Pfizer. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Novartis
novartis.com
100%
948.8K#58,822View details
Merck
merck.com
99%
656.8K#78,842View details
Astrazeneca
astrazeneca.com
90%
1.3M#48,983View details
careers.lilly.com
careers.lilly.com
74%
#60,411–
jobs.takeda.com
jobs.takeda.com
71%
#185,912–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Pfizer

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Pharmaceuticals & Distribution

3 companies that operate in the same segment as Pfizer (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Roivant Sciences
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
2014New York, New York, United StatesUSD 1.3 BUSD 8.26 M750
Amgen
Developer of pharmaceutical products for treating multiple diseases
1980Thousand Oaks, California, United StatesUSD 33.23 B28,000
AbbVie
Biopharmaceutical research and drug development are conducted globally by AbbVie.
2012Chicago, Illinois, United StatesUSD 5.33 B55,000
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Pfizer

PFIZER: Q2 SL NET PROFIT 3.13B RUPEES VS 1.89B (YOY)
Exchange Update • 4 days ago
PFIZER: Q2 EBITDA 2.6B RUPEES VS 2.3B (YOY); Q2 EBITDA MARGIN 35.94% VS 35.8% (YOY)
Exchange Update • 4 days ago
PFIZER: Q2 REVENUE 7.3B RUPEES VS 6.42B (YOY)
Exchange Update • 4 days ago
Pfizer's Litfulo Shows Significant Repigmentation in Nonsegmental Vitiligo Trials
PMLiVE • 25 days ago
Pfizer inks over $500M deal with Enodia to develop drugs targeting disease-causing proteins
BioSpace • 25 days ago
Pfizer Tukysa Regimen Gets FDA Nod for Maintenance Treatment of HER2+ Metastatic Breast Cancer
Contract Pharma • 1 month ago
Pfizer to close penicillin unit, cut around 330 jobs in Italy (PFE:NYSE)
Seeking Alpha • 1 month ago
Florida Sues Pfizer, CEO Over Alleged Misleading COVID Vaccine Marketing
The Deep Dive • 1 month ago
Pfizer eczema drug succeeds in mid-stage study (PFE:NYSE)
Seeking Alpha • 1 month ago
Nurix Therapeutics Achieves $7 Million Milestone Payment From Pfizer Collaboration
GlobeNewswire • 1 month ago
Premium access

Complete news archive for Pfizer

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Pfizer

Pfizer was founded in 1849 and raised its 1st funding round 160 years after it was founded.

Pfizer is headquartered in New York, United States. It is registered at New York, New York, United States.

Albert Bourla is the CEO of Pfizer, as recorded in our data.

Pfizer is a funded company, having raised a total of $8M across 11 funding rounds to date. The company's 1st funding round was a Grant of $42.07K, raised on Jun 2009.

Pfizer has 1,770 employees.

The primary company behind Pfizer, Pfizer Limited, reported revenue of ₹2,708 Cr for FY 2026, up 10% year on year.

Founded in 1849 and headquartered in New York, United States, operations in the pharmaceutical sector are conducted. A variety of products for disease treatments is developed, including a cancer medicine that inhibits tumor blood supply and disrupts cellular reproduction. Chantix is available to support smoking cessation. In 2022, annual revenues reached 92.95 billion, with net profit at 29.04 billion. Leadership is held by CEO Albert Bourla.

Pfizer's top competitors include Roivant Sciences, AbbVie and Gilead.

Yes, Pfizer is publicly traded on NSE under the ticker symbol PFIZER.

Pfizer has made 43 acquisitions, including Alacer, Allergan, and Amplyx Pharmaceuticals.

Pfizer has 5 investors. Key investors include Gates Foundation, European Union, Tekla Capital Management, Michigan Economic Development, and NovaQuest Capital Management.

Pfizer is associated with 4 legal entities: Pfizer Limited, Pfizer Products India Private Limited, Watson Pharma Private Limited and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available